April 15, 2025 by T.B. (FL, United States)
“N/A”
Please be aware that all information shared here at Canada Pharmacy has been medically reviewed and fact-checked for accuracy. These verifications are made by board-certified medical professionals who have the authority required to state that information related to medical conditions, symptoms, procedures and tests, and standard treatment protocols is valid and truthful. This is based on current guidelines and consensuses shared amongst medical professionals, and in representation of the latest research.
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Prescription Required
NuvaRing (etonogestrel/ethinyl estradiol vaginal ring) contains the hormones estrogen and progestin to prevent pregnancy in women.
| Fact Table | |
| Formula |
C20H24O2 |
| License |
EU EMA |
| Bioavailability |
38–48% |
| Legal status |
Rx-Only |
| Chemical Name |
Ethinylestradiol |
| Elimination half-life |
7–36 hours |
| Dosage (Strength) |
Ring |
| Pregnancy |
- |
| Brands |
NuvaRing |
| Protein binding |
97–98% |
| PubChem CID |
5991 |
| MedlinePlus |
a604032 |
| ChEBI |
4903 |
| ATC code |
G03CA01 |
| DrugBank |
DB00977 |
| KEGG |
D00554 |
| Routes of administration |
Vaginal (ring) |
Follow the instructions that come with your NuvaRing prescription and read the information leaflets. If you have any concerns or questions about your prescription, reach out to your doctor or pharmacist.
NuvaRing is a vaginal ring made of a polymer. Each ring consists of 11.7 mg of etonogestrel and 2.7 mg of ethinyl estradiol, releasing approximately 0.12 mg of etonogestrel and 0.015 mg of ethinyl estradiol per day.
Choose a position that's comfortable for you. Squeeze the ring and insert it into the vagina. You may insert the ring using the applicator for NuvaRing instead. The ring should be kept in place for three weeks. At the beginning of the fourth week, remove the ring and leave it out for one week. After removal, place the ring in a foil pouch and dispose of it properly. Keep it away from children and pets. Do not flush the ring. Leave it out for one week. A new NuvaRing should be inserted one week after the last ring was removed, even if you are experiencing menstrual bleeding.
11.7 mg of etonogestrel and 2.7 mg of ethinyl estradiol is contained in each ring.
|
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning.
|
Some side effects associated with the use of NuvaRing are as follows: vaginal inflammation, headache, mood changes, depressed mood, expulsion, discomfort, or foreign body sensation, nausea, vomiting, vaginal discharge, weight gain, vaginal discomfort, breast pain, breast discomfort, breast tenderness, painful periods, stomach pain, acne, and decreased desire to have sex.
NuvaRing (etonogestrel/ethinyl estradiol vaginal ring). Jersey City, NJ: Organon & Co.; 2022.
